更昔洛韦对巨细胞病毒血清阳性危重成人白细胞介素-6水平的影响:一项随机临床试验
这项双盲安慰剂对照随机临床试验在美国14个大学重症监护病房纳入160例因脓毒症或创伤导致呼吸衰竭的巨细胞病毒血清阳性成人,评估更昔洛韦预防对血浆白细胞介素-6水平的影响。结果显示更昔洛韦未降低白细胞介素-6水平,但显著减少血浆巨细胞病毒再激活,在意向治疗组和预设脓毒症亚组中无机械通气天数较多,其他次要结局无显著差异。作者认为当前研究不支持常规临床使用更昔洛韦作为脓毒症患者的预防药物。
要点
- 更昔洛韦组与安慰剂组白细胞介素-6第1天至14天平均变化均为-0.79 log10单位,组间差值0(95%CI -0.3至0.3),P>.99。
- 更昔洛韦组血浆巨细胞病毒再激活12%(10/84)低于安慰剂组39%(28/72),绝对风险差-27(95%CI -40至-14),P<.001。
- 意向治疗组无机械通气天数更昔洛韦组23天多于安慰剂组20天(P=.05);脓毒症亚组同样23天多于20天(P=.03)。
核心结论
- 在因脓毒症或创伤导致危重的巨细胞病毒血清阳性成人中,更昔洛韦未降低白细胞介素-6水平。
- 当前研究不支持常规临床使用更昔洛韦作为脓毒症患者的预防药物。
- 需要额外研究以确定该情境下抑制巨细胞病毒的临床疗效与安全性。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,2011年3月10日至2016年4月29日进行,随访180天(至2016年11月10日)。
- 纳入160例巨细胞病毒血清阳性成人,因脓毒症或创伤导致呼吸衰竭,来自美国14个大学重症监护病房。
- 患者按1:1随机接受静脉更昔洛韦5 mg/kg每日两次共5天,随后静脉更昔洛韦或口服缬更昔洛韦每日一次直至出院(n=84),或匹配安慰剂(n=76)。
- 160例随机患者平均年龄57岁,女性43%;156例接受至少一剂研究药物,132例(85%)完成研究。
主要发现
- 主要结局:更昔洛韦组血浆白细胞介素-6第1天至14天平均变化-0.79 log10单位(-2.06至0.48),安慰剂组-0.79 log10单位(-2.14至0.56),组间差值点估计0(95%CI -0.3至0.3),P>.99。
- 血浆巨细胞病毒再激活更昔洛韦组12%(10/84)低于安慰剂组39%(28/72),绝对风险差-27(95%CI -40至-14),P<.001。
- 意向治疗组无机械通气天数更昔洛韦组23天多于安慰剂组20天(P=.05);预设脓毒症亚组更昔洛韦组23天多于安慰剂组20天(P=.03)。
- 机械通气持续时间更昔洛韦组5天 vs 安慰剂组6天(P=.16),继发性菌血症或真菌血症发生率两组均为15%(P=.67),重症监护病房住院时间两组均为8天(P=.76),死亡率更昔洛韦组12% vs 安慰剂组15%(P=.54),均无显著差异。
临床怎么用
- 作者认为当前研究不支持常规临床使用更昔洛韦作为脓毒症患者的预防药物。
- 作者指出需要额外研究以确定该情境下抑制巨细胞病毒的临床疗效与安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of cytomegalovirus (CMV) reactivation in mediating adverse clinical outcomes in nonimmunosuppressed adults with critical illness is unknown. OBJECTIVE: To determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL-6) levels in CMV-seropositive adults who are critically ill. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled, randomized clinical trial (conducted March 10, 2011-April 29, 2016) with a follow-up of 180 days (November 10, 2016) that included 160 CMV-seropositive adults with either sepsis or trauma and respiratory failure at 14 university intensive care units (ICUs) across the United States. INTERVENTIONS: Patients were randomized (1:1) to receive either intravenous ganciclovir (5 mg/kg twice daily for 5 days), followed by either intravenous ganciclovir or oral valganciclovir once daily until hospital discharge (n = 84) or to receive matching placebo (n = 76). MAIN OUTCOMES AND MEASURES: The primary outcome was change in IL-6 level from day 1 to 14. Secondary outcomes were incidence of CMV reactivation in plasma, mechanical ventilation days, incidence of secondary bacteremia or fungemia, ICU length of stay, mortality, and ventilator-free days (VFDs) at 28 days. RESULTS: Among 160 randomized patients (mean age, 57 years; women, 43%), 156 patients received 1or more dose(s) of study medication, and 132 patients (85%) completed the study. The mean change in plasma IL-6 levels between groups was -0.79 log10 units (-2.06 to 0.48) in the ganciclovir group and -0.79 log10 units (-2.14 to 0.56) in the placebo group (point estimate of difference, 0 [95% CI, -0.3 to 0.3]; P > .99). Among secondary outcomes, CMV reactivation in plasma was significantly lower in the ganciclovir group (12% [10 of 84 patients] vs 39% [28 of 72 patients]); absolute risk difference, -27 (95% CI, -40 to -14), P < .001. The ganciclovir group had more median VFDs in both the intention-to-treat (ITT) group and in the prespecified sepsis subgroup (ITT group: 23 days in ganciclovir group vs 20 days in the placebo group, P = .05; sepsis subgroup, 23 days in the ganciclovir group vs 20 days in the placebo group, P = .03). There were no significant differences between the ganciclovir and placebo groups in duration of mechanical ventilation (5 days for the ganciclovir group vs 6 days for the placebo group, P = .16), incidence of secondary bacteremia or fungemia (15% for the ganciclovir group vs 15% for the placebo group, P = .67), ICU length of stay (8 days for the ganciclovir group vs 8 days for the placebo group, P = .76), or mortality (12% for the ganciclovir group vs 15% for the placebo group, P = .54). CONCLUSIONS AND RELEVANCE: Among CMV-seropositive adults with critical illness due to sepsis or trauma, ganciclovir did not reduce IL-6 levels and the current study does not support routine clinical use of ganciclovir as a prophylactic agent in patients with sepsis. Additional research is necessary to determine the clinical efficacy and safety of CMV suppression in this setting. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01335932.
引用
- Limaye AP, Stapleton RD, Peng L, et al. Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical Illness: A Randomized Clinical Trial. JAMA. 2017. PMID: 28829877. doi:10.1001/jama.2017.10569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。